Molecular Diagnosis of Familial Hypercholesterolemia
Authors
Abstract:
Abstract Background and objectives: Familial hypercholesterolemia (FH) is an autosomal disorder characterized by increased levels of total cholesterol and low density lipoprotein cholesterol. The FH clinical phenotype has been associated with increased risk of coronary heart disease and premature death. The mutation in LDLR gene in most cases is responsible for FH phenotype. Furthermore, other gene mutations such as apolipoprotein B- gene may cause similar results. Preliminary research indicates that the FH phenotype is also influenced by other genetic and environmental Factors therefore, routine clinical analysis such as total cholesterol and LDL-C levels in serum, for early diagnosis and treatment, are not sufficient. Molecular diagnostic investigations, because of high specifity and sensitivity near %100, administered for determining the prevalent mutations in LDLR (and probably other genes) are needed for exact diagnosis and accurate therapy. Currently, PCR-SSCP and southern blotting techniques are among the common techniques that could detect major mutations in gene. Because of wide diversity in kinds of mutations in LDLR gene, we recommend, first, determining the proband's mutation and kinds of mutation, then, performing routine test based on type of mutation. Key words: Familial hyperlipoproteinemia, LDL-R gene molecular diagnosis, mutation, Molecular Diagnostic Method
similar resources
Familial Hypercholesterolemia: From Diagnosis to Treatment
Familial hypercholesterolemia (FH) is an inherited common autosomal Mendelian disorder of lipoprotein metabolism with a population prevalence of 1 in 500. FH is characterized by severely elevated levels of low-density lipoprotein cholesterol (LDL-C), which result in surplus deposition of cholesterol in tissues. This condition leads to premature at hero sclerosis and early-onset of coronary hear...
full textFamilial hypercholesterolemia: a case report
Abstract Familial hypercholesterolemia (FH) is a hereditary dislipidemia. Patients present with extremely high level of low-density lipoprotein cholesterol (LDL-C), which is due to mutation in the gene of LDL receptor. Homozygous patients (HoFH) whose incidence is 1 in 1.000.000 are at high risk of premature aortic valve stenosis, and coronary artery atherosclerosis. In homozygous individual...
full text[Diagnosis and treatment of familial hypercholesterolemia].
Familial hypercholesterolemia is the most frequent monogenetic disease. The mode of transmission is autosomal dominant. This disease is characterized by severe elevations of low-density lipoprotein cholesterol (LDLc), with the possibility of deposits in different tissues. Unless treated appropriately, this disorder carries a high risk of vascular complications and shortened life expectancy. The...
full textClinical criteria versus DNA diagnosis in heterozygous familial hypercholesterolemia: Is molecular diagnosis superior to clinical diagnosis?
More than half of all deaths in Western society are related to arteriosclerotic cardiovascular diseases. Approximately 5% of coronary artery disease (CAD) before the age of 55 years is attributable to familial hypercholesterolemia (FH), an autosomal-dominant disease. In contrast to population hypercholesterolemia, FH typically leads to a twice-normal LDL cholesterol level for age and sex and to...
full textfamilial hypercholesterolemia: from diagnosis to treatment
familial hypercholesterolemia (fh) is an inherited common autosomal mendelian disorder of lipoprotein metabolism with a population prevalence of 1 in 500. fh is characterized by severely elevated levels of low-density lipoprotein cholesterol (ldl-c), which result in surplus deposition of cholesterol in tissues. this condition leads to premature at hero sclerosis and early-onset of coronary hear...
full textMy Resources
Journal title
volume 6 issue 1
pages 73- 84
publication date 2012-04
By following a journal you will be notified via email when a new issue of this journal is published.
No Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023